First In MS: Fingolimod Nears Market For Relapsing MS In Children, Adolescents
Executive Summary
Per initial data from Novartis's PARADIGMS study in adolescents and children, Gilenya is the first therapy shown to reduce MS relapses in younger patients in a controlled late-stage clinical study, and Novartis says it will prepare marketing submissions for the additional indication after fully analyzing the data.